Skip to main content
. 2022 Jun 20;204:105367. doi: 10.1016/j.antiviral.2022.105367

Fig. 3.

Fig. 3

Combination treatment with sunitinib/erlotinib has synergistic effect against SARS-CoV-2.

(A and B) Synergy/antagonism of sunitinib/erlotinib combination treatment on antiviral effect measured in Calu-3 cells infected with rSARS-CoV-2/Nluc (USA-WA1/2020 strain; MOI = 0.05) at 24 hpi via Nluc assays (A) and on cellular viability measured at 24 hpi in the same samples via alamarBlue assays (B). Data represents the differential surface analysis at the 95% confidence interval (CI), analyzed via the MacSynergy II program. Synergy and antagonism are indicated by the peaks above and below the theoretical additive plane, respectively. The level of synergy or antagonism is depicted by the color code on the figure. Data are representative of two independent experiments with three replicates each.